SIRT2 and type 2 diabetes mellitus: In summary, our findings demonstrate pathogenic significance of excessive α-ENaC in β-cell dysfunction and indicate the necessity of α-ENaC-targeting therapies to prevent SIRT2 loss and inhibit T2DM development.